Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2019.0282


Individualized prediction of drug response and relapse risk for patients without distant metastasis.

E. Hanisch, MD.


Minimal residual disease after complete tumor resection (R0) and adjuvant treatment is the predominant cause of relapse and death. Combining clinic-pathologic and genetic characteristics as well as TNM staging can either accurately identify these minimal microscopic disease or molecules responsible for subsequent relapse. Based on the genome – (genomic clones) – phenotypic event (drug resistance, relapse) map, this article summarizes the potential and challenges for the development of prognostic and predictive biomarkers to predict individualized drug response and prevent early and late relapse.

(Citation: Gastric & Breast Cancer 2019; 14(1): 33-39)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 10 June 2019